$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Hematology
Hematology
吉妥珠单抗在儿童急性髓性白血病中的用量
2025-10-19 11:44:20
Check Details
慢淋白血病患者使用维奈托克的禁忌和注意事项
2025-10-19 11:44:20
Check Details
治疗慢性髓系白血病的波舒替尼在中国批准上市了吗?
2025-10-19 11:44:20
Check Details
FDA批准波舒替尼用于慢性粒细胞白血病的治疗
2025-10-19 11:44:20
Check Details
吉妥珠单抗多少钱一支?在哪可以买到?
2025-10-19 11:44:20
Check Details
慢性粒细胞白血病新疗法-波舒替尼
2025-10-19 11:44:20
Check Details
波舒替尼的出现,让慢性髓系白血病患者有了新的希望!
2025-10-19 11:44:20
Check Details
白血病新药吉妥珠单抗图片及药物介绍
2025-10-19 11:44:20
Check Details
米哚妥林|雷德帕斯(MIDOSTAURIN)适应症是什么?优势在哪里?
2025-10-19 11:44:20
Check Details
新药SNDX-5613用于治疗混合系白血病和急性白血病
2025-10-19 11:44:20
Check Details
靶向药物米哚妥林(MIDOSTAURIN)治疗白血病的疗效
2025-10-19 11:44:20
Check Details
依鲁替尼联用维奈托克的双靶向治疗效果怎么样?
2025-10-19 11:44:20
Check Details
1
2
...
615
616
617
618
619
620
621
...
938
939
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
In-Depth Analysis of Selinexor (Xpovio): A Novel Nuclear Export Blockade Option for Relapsed/Refractory Multiple Myeloma and Latest Clinical Advances
2
Acalabrutinib BTK Covalent Inhibition: CLL/SLL Signaling Blockade, Non-Selective Effects, and Progression Monitoring
3
Bosutinib for Ph+ CML: Eligible Populations, Food-Dependent Dosing, Diarrhea and Hepatotoxicity Monitoring
4
Venetoclax BCL-2 Inhibitor: CLL/SLL and AML Ramp-Up, Tumor Lysis Prevention, and Selected Overseas Combination Updates
5
First-Line Pirtobrutinib Without 17p Deletion in CLL/SLL: Noncovalent BTK vs BR, Median PFS Not Reached, HR 0.20
6
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
7
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
8
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
9
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
10
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
11
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
12
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment